The Clinical and Cost Effectiveness of Dasatinib Versus Nilotinib for The First and Second Line Treatment of People with Chronic Myeloid Leukaemia
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.201
https://www.valueinhealthjournal.com/article/S1098-3015(17)30535-1/fulltext
Title :
The Clinical and Cost Effectiveness of Dasatinib Versus Nilotinib for The First and Second Line Treatment of People with Chronic Myeloid Leukaemia
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30535-1&doi=10.1016/j.jval.2017.08.201
First page :
A433
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
182